Skip Navigation







Temazepam is an orally available benzodiazepine used in the therapy of insomnia.  As with most benzodiazepines, temazepam therapy has not been associated with serum aminotransferase or alkaline phosphatase elevations, and clinically apparent liver injury from temazepam has not been reported and must be very rare, if it occurs at all.



Temazepam (tem az' e pam) is a benzodiazepine that is widely used as a sleeping aid in the therapy of insomnia.  The soporific activity of the benzodiazepines is mediated by their ability to enhance gamma-aminobutyric acid (GABA) mediated inhibition of synaptic transmission through binding to the GABA A receptor.  Temazepam was approved in the United States in 1981, and currently more than 8 million prescriptions are filled yearly.  Current indications are for the short term treatment of insomnia.  Temazepam is available in capsules of 7.5, 15, 22 and 30 mg in several generic forms and under the brand name Restoril.  The recommended initial dose for insomnia is 7.5 mg before bedtime, increasing as needed to a maximum dose of 30 mg.  The most common side effects of temazepam are dose related and include daytime drowsiness, lethargy, ataxia, dysarthria and dizziness.  Tolerance develops to these side effects, but tolerance may also develop to the effects on insomnia.



Temazepam, like other benzodiazepines, is rarely associated with serum ALT elevations, and clinically apparent liver injury from temazepam is extremely rare, if it occurs at all.  There have been no case reports of symptomatic, acute liver injury from temazepam.  Cases of clinically apparent liver injury have been reported with other benzodiazepines including alprazolam, chlordiazepoxide, clonazepam, diazepam, flurazepam and triazolam.  The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic and mild-to-moderate in severity with a latency of 1 to 6 months.  Fever and rash are uncommon as is autoantibody formation.


Mechanism of Injury

Temazepam is metabolized by the liver to inactive metabolites.  Liver injury from benzodiazepines is probably due to the toxic effects of a rarely produced intermediate metabolite.


Outcome and Management

The case reports of hepatic injury due to benzodiazepines were followed by prompt and complete recovery upon stopping the medication, without evidence of residual or chronic injury.  No cases of acute liver failure or chronic liver injury due to temazepam have been described.  There is no information about cross reactivity with other benzodiazepines, but some degree of cross sensitivity may occur.


Drug Class:  Sedatives and Hypnotics, Benzodiazepines


Top of page



Temazepam – Generic, Restoril®

Sedatives and Hypnotics


Product labeling at DailyMed, National Library of Medicine, NIH


Top of page

Temazepam 846-50-4 C16-H13-Cl-N2-O2 Chemical Structure for Temazepam

Top of page



References updated: 4 December 2013

  1. Zimmerman HJ. Benzodiazepines. Psychotropic and anticonvulsant agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 491-3.  (Expert review of benzodiazepines and liver injury published in 1999; mentions rare instances of cholestatic hepatitis have been reported due to alprazolam, chlordiazepoxide, diazepam, flurazepam, and triazolam, and hepatocellular injury with clorazepate and clotiazepam, but no reports of hepatic injury with lorazepam, oxazepam or temazepam).

  2. Larrey D. Benzodiazepines. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007, pp. 517.  (Review of drug induced liver injury published in 2007; rare instances of acute liver injury [usually cholestatic] have been reported with alprazolam, chlordiazepoxide, diazepam, flurazepam and triazolam; a hepatitis-like pattern has been reported with clonazepam and clorazepate).

  3. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In, Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006, pp. 401-27.  (Textbook of pharmacology and therapeutics).

  4. Davion T, Capron-Chivrac D, Andrejak M, Capron JP. [Hepatitis due to antiepileptic agents] Gastroenterol Clin Biol 1985; 9: 117-26. PubMed Citation  (Review of hepatotoxicity of anticonvulsants; among benzodiazepines, cases of cholestatic hepatitis have been linked to chlordiazepoxide and diazepam, but liver injury from this class of drugs is exceptionally rare).

  5. Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999; 3: 433-64, vii. Erratum in: Clin Liver Dis 1999; 3: 917. PubMed Citation  (Review of drug induced cholestatic syndromes, listing many causes including chlordiazepoxide and flurazepam; “Benzodiazepines may cause cholestatic injury, although this is rare”).

  6. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118: 281-90. PubMed Citation  (Review of hepatotoxicity of all anticonvulsants focusing upon phenytoin, valproate, carbamazepine; “Furthermore, hepatoxicity has not been convincingly shown to be associated with the use of benzodiazepines”).

Top of page

  1. PubMed logoRecent References on Temazepam

  2. Clinical Trials logoTrials on Temazepam

Top of page